Trimistin-Darnytsia (triamcinolone acetonide) ointment 14 g. tube

Description

Trimistin-Darnytsia (triamcinolone acetonide) ointment 14 g. tube

Composition

active substances: 1 g of ointment contains triamcinolone acetonide micronized 0.25 mg, miramistin 5 mg;

Excipients: propylene glycol, betacyclodextrin, cetyl alcohol, stearyl alcohol, purified water.

Dosage form

Ointment.

Basic physical and chemical properties: ointment of white color, gel-like consistency, with a weak specific odor, in appearance should be homogeneous.

Pharmacotherapeutic group

Corticosteroids in combination with antiseptics.
ATX code D07B B03.

Pharmacological properties

Ointment Trimistin-Darnytsia – a combined drug for topical use. Active substances – triamcinolone acetonide and miramistin.

• Triamcinolone is a fluorinated glucocorticosteroid with pronounced anti-inflammatory, anti-allergic and anti-exudative effects. Interacting with a specific protein receptor in target tissues, regulates the expression of corticoid-dependent genes and affects protein synthesis. Reduces the formation, release and activity of inflammatory mediators (histamine, kinin, prostaglandins, lysosomal enzymes). Inhibits cell migration to the site of inflammation; reduces vasodilation and vascular permeability in the site of inflammation. Stabilizes lysosomal enzymes of leukocyte membranes; inhibits antibody synthesis and disrupts antigen recognition. Inhibits the release of interleukin-1, interleukin-2, gamma-interferon from lymphocytes and macrophages. Induces the formation of lipocortin, inhibits the release of eosinophils inflammatory mediators and stabilizes the membranes of mast cells. All of these effects suppress the inflammatory response in tissues in response to mechanical, chemical, or immune damage.
• Miramistin is a broad-spectrum antiseptic that has a bactericidal effect (hydrophobic interaction with the membranes of microorganisms leads to their destruction). Effective against gram-positive (including Staphylococcus spp., Streptococcus spp., Streptococcus pneumonia) – mainly and gram-negative microorganisms (including aerobes and anaerobes), spore-forming and spore-forming microflora in the form of monocultures with anticulture and anticrobial ). It has antifungal action on ascomycetes of the genus Aspergillus and the genus Penicillium, yeast fungi (Rhodotorula rubra, Torulopsis gabrata and others) and yeast (Candida albicans, Candida tropicalis, Candida krusei and others), dermatophytes, Trichoicto Trichorictonic Trichophyton ( , Trichophyton violaceum, Epidermophyton Kaufman-Wolf, Epidermophyton floccosum, Microsporum gypseum, Microsporum canis and others), as well as other pathogenic fungi, such as Pityrosporum orbiculare (Malassezia furfur), in the form of monocultures and microbial associations, including medicines. Miramistin reduces the resistance of microorganisms to antibiotics. Effectively prevents wound infection by activating regeneration processes.

Indications for use

The drug Trimistin-Darnytsia is used and prescribed for inflammatory skin diseases, including those complicated by fungal or bacterial infections: atopic dermatitis, eczema, neurodermatitis, parapsoriasis, psoriasis in exudative form and a progressive stage, pemphigus, seborrheic dermatitis, contact dermatitis, Dühring’s dermatitis, photodiscous disease , skin lymphoma.

Contraindications

The drug Trimistin-Darnytsia has a number of contraindications:

• individual intolerance to the ingredients;
• viral skin lesions, in particular with chickenpox and herpes simplex;
• lupus;
• parasitic infections (scabies) syphilitic skin lesions;
• skin reactions after vaccination;
• widespread plaque psoriasis;
• diaper rash, from wet diapers;
• leg ulcers, varicose veins, genital and perianal itching, facial skin lesions (acne vulgaris, rosacea, perioral dermatitis);
• skin cancer;
• dry peeling of the skin.

Pregnancy and breastfeeding period

The drug Trimistin-Darnytsia is contraindicated for use during the I trimester of pregnancy, as well as during lactation, in the II and III trimester, use is possible only upon the recommendation of the attending physician.

Mode of application

The drug Trimistin-Darnytsia is intended for topical use.
Before applying the ointment, erosive areas of the skin should be washed with a solution of hydrogen peroxide 3%, boric acid 1% or chlorhexidine bigluconate 0.05%. If necessary, the drug is applied to the bandage.
After the standard treatment of damaged skin has been carried out, it is necessary to apply a thin layer of ointment 1-2 times a day, but not more than 15 g of the drug. Also, the ointment is used under an occlusive dressing, but not more than 10 g per day.
The duration of therapy is determined by the doctor for each patient individually.

Overdose

The application of Trimistin-Darnytsia ointment in higher dosages and on large areas of the skin can cause the development of systemic side and local reactions. It is necessary to apply symptomatic treatment, but to cancel the drug immediately, it is not worth it, this must be done gradually, reducing the dose.

Adverse reactions

Side effects when using the drug Trimistin-Darnytsia from various systems:

• organs of vision: exophthalmos, edema of the papilla of the optic nerve, glaucoma, exophthalmos, corneal ulcers and cataracts, especially in children;
• gastrointestinal tract: gastrointestinal bleeding, gastric bleeding, gastrointestinal perforation, pancreatitis, esophagitis, peptic ulcer;
• nervous system: convulsions, mental disorders, dizziness, increased intracranial pressure, headache, insomnia;
• cardiovascular system: arterial hypertension, heart failure;
• immune system: hypersensitivity reactions;
• skin and subcutaneous tissue: burning sensation, hyperemia, irritation, hypersensitivity, dryness, thinning of the skin, hirsutism, folliculitis, acne rash, perioral dermatitis, hypopigmentation, telangiectasia and erythema of the face, increased sweating, allergic contact dermatitis, retardation wounds, secondary infections, increased edema, oozing, itching, skin atrophy, contact eczema, slowing reactions during skin tests, steroid acne and purpura;
• musculoskeletal system and connective tissues: steroid myopathy, growth retardation in children, osteonecrosis, osteoporosis, aseptic necrosis;
• infections and parasitic diseases: masking the course of infections, activation of latent infections, opportunistic infections.
• systemic manifestations: suppression of the function of the adrenal cortex, Itsenko-Cushing’s syndrome, decreased tolerance to carbohydrates;
• water-electrolyte metabolism: secondary insufficiency of the adrenal cortex, hypokalemia, sodium and water retention in the body, hypokalemic alkalosis, arterial hypertension;
• laboratory abnormalities: negative nitrogen balance, increased intraocular pressure, slowing reactions during skin tests.